Latest Peplin news



news 

01-Feb-10

LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition read more

21-Dec-09

Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp read more

12-Nov-09

Letter to our CDI Holders read more


API Manufacturing

Peplin operates a commercial-scale manufacturing facility located in Southport, Queensland, Australia for API production of our proprietary, lead compound PEP005 (ingenol mebutate), a well characterized and purified single molecular entity sourced from a rapidly growing plant called Euphorbia peplus. The entire production process involves cultivation, post-harvest processing, extraction, purification and formulation of PEP005 using strict quality standards for use in clinical trials.

Various contractors based in southeast Queensland and internationally support these activities.